Interferon-β modulates inflammatory response in cerebral ischemia

Ping Chang Kuo, Barbara A. Scofield, I. Chen Yu, Fen-Lei Chang, Doina Ganea, Jui Hung Yen

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background-Stroke is a leading cause of death in the world. In > 80% of strokes, the initial acute phase of ischemic injury is due to the occlusion of a blood vessel resulting in severe focal hypoperfusion, excitotoxicity, and oxidative damage. Interferon-β (IFNβ), a cytokine with immunomodulatory properties, was approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis for more than a decade. Its anti-inflammatory properties and well-characterized safety profile suggest that IFNβ has therapeutic potential for the treatment of ischemic stroke. Methods and Results-We investigated the therapeutic effect of IFNβ in the mouse model of transient middle cerebral artery occlusion/reperfusion. We found that IFNb not only reduced infarct size in ischemic brains but also lessened neurological deficits in ischemic stroke animals. Further, multiple molecular mechanisms by which IFNb modulates ischemic brain inflammation were identified. IFNb reduced central nervous system infiltration of monocytes/macrophages, neutrophils, CD4+ T cells, and γδ T cells; inhibited the production of inflammatory mediators; suppressed the expression of adhesion molecules on brain endothelial cells; and repressed microglia activation in the ischemic brain. Conclusions-Our results demonstrate that IFNβ exerts a protective effect against ischemic stroke through its anti-inflammatory properties and suggest that IFNβ is a potential therapeutic agent, targeting the reperfusion damage subsequent to the treatment with tissue plasminogen activator.

Original languageEnglish (US)
Article numbere002610
JournalJournal of the American Heart Association
Volume5
Issue number1
DOIs
StatePublished - 2016

Fingerprint

Brain Ischemia
Interferons
Stroke
Brain
Anti-Inflammatory Agents
T-Lymphocytes
Relapsing-Remitting Multiple Sclerosis
Middle Cerebral Artery Infarction
Microglia
Therapeutic Uses
Tissue Plasminogen Activator
Encephalitis
United States Food and Drug Administration
Reperfusion Injury
Reperfusion
Blood Vessels
Monocytes
Cause of Death
Neutrophils
Central Nervous System

Keywords

  • CD4 T cells
  • Interferon-β
  • Ischemic stroke
  • Microglia
  • Monocytes/macrophages
  • Neuroinflammation
  • Reperfusion
  • γδ T cells

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Interferon-β modulates inflammatory response in cerebral ischemia. / Kuo, Ping Chang; Scofield, Barbara A.; Yu, I. Chen; Chang, Fen-Lei; Ganea, Doina; Yen, Jui Hung.

In: Journal of the American Heart Association, Vol. 5, No. 1, e002610, 2016.

Research output: Contribution to journalArticle

Kuo, Ping Chang ; Scofield, Barbara A. ; Yu, I. Chen ; Chang, Fen-Lei ; Ganea, Doina ; Yen, Jui Hung. / Interferon-β modulates inflammatory response in cerebral ischemia. In: Journal of the American Heart Association. 2016 ; Vol. 5, No. 1.
@article{278f185d12594cb0ba73ccb4b6cf499b,
title = "Interferon-β modulates inflammatory response in cerebral ischemia",
abstract = "Background-Stroke is a leading cause of death in the world. In > 80{\%} of strokes, the initial acute phase of ischemic injury is due to the occlusion of a blood vessel resulting in severe focal hypoperfusion, excitotoxicity, and oxidative damage. Interferon-β (IFNβ), a cytokine with immunomodulatory properties, was approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis for more than a decade. Its anti-inflammatory properties and well-characterized safety profile suggest that IFNβ has therapeutic potential for the treatment of ischemic stroke. Methods and Results-We investigated the therapeutic effect of IFNβ in the mouse model of transient middle cerebral artery occlusion/reperfusion. We found that IFNb not only reduced infarct size in ischemic brains but also lessened neurological deficits in ischemic stroke animals. Further, multiple molecular mechanisms by which IFNb modulates ischemic brain inflammation were identified. IFNb reduced central nervous system infiltration of monocytes/macrophages, neutrophils, CD4+ T cells, and γδ T cells; inhibited the production of inflammatory mediators; suppressed the expression of adhesion molecules on brain endothelial cells; and repressed microglia activation in the ischemic brain. Conclusions-Our results demonstrate that IFNβ exerts a protective effect against ischemic stroke through its anti-inflammatory properties and suggest that IFNβ is a potential therapeutic agent, targeting the reperfusion damage subsequent to the treatment with tissue plasminogen activator.",
keywords = "CD4 T cells, Interferon-β, Ischemic stroke, Microglia, Monocytes/macrophages, Neuroinflammation, Reperfusion, γδ T cells",
author = "Kuo, {Ping Chang} and Scofield, {Barbara A.} and Yu, {I. Chen} and Fen-Lei Chang and Doina Ganea and Yen, {Jui Hung}",
year = "2016",
doi = "10.1161/JAHA.115.002610",
language = "English (US)",
volume = "5",
journal = "Journal of the American Heart Association",
issn = "2047-9980",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Interferon-β modulates inflammatory response in cerebral ischemia

AU - Kuo, Ping Chang

AU - Scofield, Barbara A.

AU - Yu, I. Chen

AU - Chang, Fen-Lei

AU - Ganea, Doina

AU - Yen, Jui Hung

PY - 2016

Y1 - 2016

N2 - Background-Stroke is a leading cause of death in the world. In > 80% of strokes, the initial acute phase of ischemic injury is due to the occlusion of a blood vessel resulting in severe focal hypoperfusion, excitotoxicity, and oxidative damage. Interferon-β (IFNβ), a cytokine with immunomodulatory properties, was approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis for more than a decade. Its anti-inflammatory properties and well-characterized safety profile suggest that IFNβ has therapeutic potential for the treatment of ischemic stroke. Methods and Results-We investigated the therapeutic effect of IFNβ in the mouse model of transient middle cerebral artery occlusion/reperfusion. We found that IFNb not only reduced infarct size in ischemic brains but also lessened neurological deficits in ischemic stroke animals. Further, multiple molecular mechanisms by which IFNb modulates ischemic brain inflammation were identified. IFNb reduced central nervous system infiltration of monocytes/macrophages, neutrophils, CD4+ T cells, and γδ T cells; inhibited the production of inflammatory mediators; suppressed the expression of adhesion molecules on brain endothelial cells; and repressed microglia activation in the ischemic brain. Conclusions-Our results demonstrate that IFNβ exerts a protective effect against ischemic stroke through its anti-inflammatory properties and suggest that IFNβ is a potential therapeutic agent, targeting the reperfusion damage subsequent to the treatment with tissue plasminogen activator.

AB - Background-Stroke is a leading cause of death in the world. In > 80% of strokes, the initial acute phase of ischemic injury is due to the occlusion of a blood vessel resulting in severe focal hypoperfusion, excitotoxicity, and oxidative damage. Interferon-β (IFNβ), a cytokine with immunomodulatory properties, was approved by the US Food and Drug Administration for the treatment of relapsing-remitting multiple sclerosis for more than a decade. Its anti-inflammatory properties and well-characterized safety profile suggest that IFNβ has therapeutic potential for the treatment of ischemic stroke. Methods and Results-We investigated the therapeutic effect of IFNβ in the mouse model of transient middle cerebral artery occlusion/reperfusion. We found that IFNb not only reduced infarct size in ischemic brains but also lessened neurological deficits in ischemic stroke animals. Further, multiple molecular mechanisms by which IFNb modulates ischemic brain inflammation were identified. IFNb reduced central nervous system infiltration of monocytes/macrophages, neutrophils, CD4+ T cells, and γδ T cells; inhibited the production of inflammatory mediators; suppressed the expression of adhesion molecules on brain endothelial cells; and repressed microglia activation in the ischemic brain. Conclusions-Our results demonstrate that IFNβ exerts a protective effect against ischemic stroke through its anti-inflammatory properties and suggest that IFNβ is a potential therapeutic agent, targeting the reperfusion damage subsequent to the treatment with tissue plasminogen activator.

KW - CD4 T cells

KW - Interferon-β

KW - Ischemic stroke

KW - Microglia

KW - Monocytes/macrophages

KW - Neuroinflammation

KW - Reperfusion

KW - γδ T cells

UR - http://www.scopus.com/inward/record.url?scp=84997831964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84997831964&partnerID=8YFLogxK

U2 - 10.1161/JAHA.115.002610

DO - 10.1161/JAHA.115.002610

M3 - Article

C2 - 26747000

AN - SCOPUS:84997831964

VL - 5

JO - Journal of the American Heart Association

JF - Journal of the American Heart Association

SN - 2047-9980

IS - 1

M1 - e002610

ER -